Skip to main content
Premium Trial:

Request an Annual Quote

454 Installs its Sequencing Platform at Broad Institute

NEW YORK, March 25 (GenomeWeb News) - 454 Life Sciences has completed the installation of its first commercial genome sequencing system at Harvard University's and MIT's Broad Institute, the company said today.

 

454, a subsidiary of CuraGen, has developed a system that accelerates sequencing processes through the use of microfluidics and other methods of miniaturizing current technology. Previously, the company, based in Brandford, Conn., offered use of the system as a service.

 

Financial details were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.